Business Context and Reporting Period
This Form 8-K reports the consummation of the initial public offering (IPO) by Panacea Acquisition Corp. (a Special Purpose Acquisition Company or SPAC) on July 6, 2020. The filing details the issuance of units, private placement sales, and the establishment of a trust account to fund a future business combination. Note: The request metadata references "Nuvation Bio Inc.," but the filing text explicitly identifies the registrant as Panacea Acquisition Corp.
Key Financial Metrics
- IPO Gross Proceeds: $143,750,000 from the sale of 14,375,000 Units at $10.00 per Unit (including 1,875,000 Units from the underwriters' full exercise of their option).
- Private Placement Proceeds: $4,875,000 from the sale of 487,500 Private Placement Units (390,000 to the Sponsor and 97,500 to Cowen Investments) at $10.00 per Unit.
- Total Trust Account Funding: $143,750,000 (comprised of IPO proceeds and Private Placement proceeds) deposited into a U.S.-based trust account at J.P. Morgan Chase Bank, N.A.
- Warrant Exercise Price: $11.50 per share for whole warrants.
- Revenue/Profit/Cash Flow: Not applicable. As a newly formed SPAC, the filing does not report operating revenue, profit, or operating cash flow.
Material Changes and Structure
The primary material event is the transition from a private entity to a public company via the IPO. Key structural details include:
- Unit Composition: Each Unit consists of one share of Class A common stock and one-third of one redeemable warrant.
- Private Placement Terms: Private Placement Units are subject to transfer restrictions and registration rights. Their underlying warrants are non-redeemable by the Company and may be exercised on a cashless basis.
- Trust Account Restrictions: Funds in the trust account generally cannot be released until the completion of an initial business combination, a vote to amend the certificate of incorporation regarding redemption rights, or the redemption of all public shares if a combination is not completed within 24 months of the IPO.
Outlook, Risks, and Contingencies
- Business Combination Deadline: The Company must complete an initial business combination within 24 months from the closing of the IPO (by July 6, 2022), or it must redeem all public shares.
- Redemption Rights: Public shareholders have the right to redeem their shares in connection with a business combination or if the Company fails to complete one within the specified timeframe.
- Forward Purchase Agreement: The Company entered into a Forward Purchase Agreement with the Sponsor and related funds, indicating a commitment to provide additional capital or support for a future transaction.
- Emerging Growth Company: The registrant is designated as an emerging growth company.
Investor Verification Checklist
- Verify the exact deadline for the initial business combination (24 months from July 6, 2020).
- Confirm the terms of the Forward Purchase Agreement to understand potential future capital commitments from the Sponsor.
- Review the specific redemption rights and conditions under which the trust account funds may be released.
- Check the status of the underwriters' option exercise (confirmed as fully exercised in this filing).
- Monitor subsequent filings for the identification of a target company for the business combination.